Find Ophthalmology Drugs in Phase II Clinical Development

Lead Product(s): APX3330

Therapeutic Area: Ophthalmology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Ocuphire Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 22, 2020

Details:

Under the terms and conditions of the deal, Ocuphire earns an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330.

Lead Product(s): Dexamethasone

Therapeutic Area: Ophthalmology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 22, 2020

Details:

The Phase 2 trial data is the first controlled study of OCS-01 for the treatment of DME.

Lead Product(s): NRO-1

Therapeutic Area: Ophthalmology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 16, 2020

Details:

The Phase 2 clinical trial is a multicenter, randomized, double-masked, vehicle-controlled clinical trial that will evaluate the safety and efficacy of NRO-1 in patients with dry eye disease.

Lead Product(s): Avacincaptad Pegol

Therapeutic Area: Ophthalmology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2020

Details:

This 2nd pivotal trial will be an international, sham controlled clinical trial enrolling 400 patients to be randomized to receive monthly administration of Zimura 2 mg or sham.

Lead Product(s): TP-03

Therapeutic Area: Ophthalmology

Highest Development Status: Phase II Product Type: Undisclosed

Partner/Sponsor/Collaborator: Vivo Capital

Deal Size: $60.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing January 08, 2020

Details:

The financing will enable Tarsus Pharma's Phase 2b/3 trial for lead product TP-03 in Demodex blepharitis and additional clinical pipeline development.